Wet

Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights

Retrieved on: 
Thursday, February 8, 2024

Wet AMD poses a particularly severe threat to vision, necessitating treatment with biologic therapies administered in four to twelve-week intervals.

Key Points: 
  • Wet AMD poses a particularly severe threat to vision, necessitating treatment with biologic therapies administered in four to twelve-week intervals.
  • However, the current treatment landscape often burdens elderly patients with high treatment frequencies, impacting their ability to attend all appointments.
  • Spherix Global Insights conducted an in-depth analysis through its RealTime Dynamix™ report series, delving into the evolving perceptions of ophthalmologists (n=101) regarding approved therapies for wet AMD.
  • In January 2024, ophthalmologists were surveyed on their preferred biologic treatment for wet AMD among other topics.

Xpander and Xpander Cross HEV Models Premiere in Thailand, Featuring Safe, Secure and Exhilarating Driving Experience of Electrified Vehicles

Retrieved on: 
Thursday, February 1, 2024

The newly-added HEV models combine Mitsubishi Motors' trademark electrification and all-wheel control technologies to raise the appeal of the Xpander series to another level.

Key Points: 
  • The newly-added HEV models combine Mitsubishi Motors' trademark electrification and all-wheel control technologies to raise the appeal of the Xpander series to another level.
  • Newly developed based on the brand's plug-in hybrid electric vehicles (PHEVs), the HEV system delivers an eco-friendly and exhilarating driving experience unique to electrified vehicles.
  • Moreover, drivers can actively choose EV driving according to the situation, such as driving in quiet residential areas early in the morning.
  • Hybrid driving also kicks in when driving at high speeds to run using the engine with assistance from the motor (Figure 3).

EQS-News: Deutsche Postbank Funding Trust III: Half Year Report as of 30th June 2023

Retrieved on: 
Tuesday, November 7, 2023

Deutsche Postbank Funding Trust III: Half Year Report as of 30th June 2023

Key Points: 
  • Deutsche Postbank Funding Trust III: Half Year Report as of 30th June 2023
    The issuer is solely responsible for the content of this announcement.
  • Deutsche Postbank Funding Trust III hereby announces that the half year report as of 30th June 2023 pursuant to Section 5:25c of the Netherlands Financial Supervision Act (Wet op het financieel toezicht) is available at: https://investor-relations.db.com/creditors/prospectuses/reports-deutsch...
    01.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
  • The issuer is solely responsible for the content of this announcement.
  • The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Teleperformance SE: Final Results of the Offer for Majorel

Retrieved on: 
Friday, November 3, 2023

This press release does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in Teleperformance or Majorel.

Key Points: 
  • This press release does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in Teleperformance or Majorel.
  • A total of 78,984,447 Shares have been tendered against the Share Consideration during the Offer Period and the Post-Acceptance Period.
  • Teleperformance intends to offer the amount of the Cash Consideration (i.e., EUR 30 per Share) as part of these squeeze-out proceedings.
  • Reference is made to Section 6.13 (Consequences of the Offer for non-tendering Shareholders) of the Offer Memorandum.

Teleperformance declares Offer for Majorel unconditional 98.45% of Shares tendered under the Offer – Opening of the Post-Acceptance Period

Retrieved on: 
Friday, October 20, 2023

As a result, Teleperformance declares the Offer unconditional (doet gestand) and the Post-Acceptance Period will start as from 23 October 2023 for a 2-week period.

Key Points: 
  • As a result, Teleperformance declares the Offer unconditional (doet gestand) and the Post-Acceptance Period will start as from 23 October 2023 for a 2-week period.
  • Shareholders who have elected to receive the Share Consideration during the Offer Period or the Post-Acceptance Period will receive on the Second Settlement Date Teleperformance shares at an exchange ratio of 30/217.
  • Further information on the Post-Acceptance Period is included in Section 5.8 (Post-Acceptance Period) of the Offer Memorandum.
  • A maximum of 4,608,295 Teleperformance shares is available for issue under the Share Consideration, (i.e., a maximum of 33,333,334 Shares can be exchanged for Teleperformance shares).

New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss

Retrieved on: 
Thursday, July 20, 2023

“The clinical and real-world data at ASRS reinforce the improvement in outcomes brought by Vabysmo in two leading causes of vision loss, particularly new analyses suggesting that Vabysmo is associated with less vision-impacting fibrosis than aflibercept,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.

Key Points: 
  • “The clinical and real-world data at ASRS reinforce the improvement in outcomes brought by Vabysmo in two leading causes of vision loss, particularly new analyses suggesting that Vabysmo is associated with less vision-impacting fibrosis than aflibercept,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.
  • Wet AMD and DME are two leading causes of vision loss, together affecting more than two million people in the United States and 40 million people globally.
  • Data will also further support how increased intervals between doses of Vabysmo to treat wet AMD and DME, compared to aflibercept, do not compromise outcomes.
  • Elevatum Study Design and Rationale: A Phase 4 Trial of Faricimab (VABYSMO) in Underrepresented Patients With Diabetic Macular Edema

Alta Copper Appoints Andrew Hamilton to the Board of Directors

Retrieved on: 
Monday, July 10, 2023

VANCOUVER, British Columbia, July 10, 2023 (GLOBE NEWSWIRE) -- Alta Copper Corp. (TSX: ATCU; OTCQX: ATCUF; BVL: ATCU) (“Alta Copper” or the “Company”) announces the appointment of Mr. Andrew Hamilton as a director of the Company.

Key Points: 
  • VANCOUVER, British Columbia, July 10, 2023 (GLOBE NEWSWIRE) -- Alta Copper Corp. (TSX: ATCU; OTCQX: ATCUF; BVL: ATCU) (“Alta Copper” or the “Company”) announces the appointment of Mr. Andrew Hamilton as a director of the Company.
  • “We are pleased to announce the appointment of Andrew Hamilton to the Board of Directors of Alta Copper.
  • Mr. Andrew Hamilton is Technical Director of Fortescue Metals with the Corporate Strategy Team.
  • Mr. Hamilton held various roles on the US$3.9bn IBJV project including Project Director and Technical Director.

Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD

Retrieved on: 
Saturday, June 10, 2023

BEDFORD, Mass., June 10, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced 12-month data from its Phase 1 U.S. clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel implant, for the treatment of wet age-related macular degeneration (wet AMD). OTX-TKI is also being developed for the treatment of diabetic retinopathy and other retinal diseases.

Key Points: 
  • An investigational, bioresorbable hydrogel intravitreal implant, OTX-TKI is designed to continuously deliver a potent tyrosine kinase inhibitor, axitinib, for the treatment of wet AMD and other VEGF-mediated retinal diseases.
  • The 12-month data demonstrated maintenance of controlled wet AMD subjects comparable to aflibercept injections every eight weeks with a single administration of OTX-TKI.
  • “Pharmacodynamic effects observed in this trial support the characteristics of a treatment for wet AMD with durability between 9 to 12 months with a single injection.
  • We are excited for what these data could mean for patients living with VEGF-mediated retinal diseases.”
    Summary of 12-Month Topline Data from U.S.

Recycling: what you can and can't recycle and why it's so confusing

Retrieved on: 
Thursday, June 1, 2023

No, I didn’t know what this term meant until recently either – apparently it’s when people try to recycle items that should be thrown away instead.

Key Points: 
  • No, I didn’t know what this term meant until recently either – apparently it’s when people try to recycle items that should be thrown away instead.
  • New rules will ask people to stop “over-recycling” and to be more careful about what they put in their recycling bins.
  • It’s no wonder that many admit it’s easier just to throw something in the bin instead of working out if it can be recycled.

Waste not

    • While huge strides are being made in this area, we are still some way off all packaging being made in this way in a cost-effective manner.
    • One of the main issues is there are differences in how recycling waste is collected across the UK – this can even be the case from one street to another.
    • But if you’ve thrown yours away – or perhaps recycled it - the information should also be on your local authorities’ website.
    • One of the main reasons there are currently variations in what different authorities do or don’t recycle is based on what the waste management companies they use to recyclable waste after it’s collected.

Recycling tips

    • As with crisp packets and soft plastics, things such as pet food pouches can be recycled too but again not typically via your household collections – instead, these can often go to larger supermarkets for recycling.
    • But it’s a good idea to rinse them to avoid contamination during the recycling process (and to stop your bin smelling in between collections).
    • This is because opaque trays cannot be sorted from other types of plastic in a recycling facility as light cannot pass through them.
    • Although it definitely isn’t a case of the more the merrier when it comes to recycling, the better we are as a society at dealing with our waste and not just sending it to landfill, the better our air and environment will be for us and future generations.

Diebold Nixdorf, Incorporated Enters into Global Debt Restructuring Support Agreement with Key Financial Stakeholders; Contemplated Transaction Expected to Significantly Reduce Leverage, Provide Substantial Additional Liquidity and Support Seamless Ongoin

Retrieved on: 
Tuesday, May 30, 2023

The restructuring is expected to significantly reduce debt and leverage levels and provide substantial additional liquidity to support seamless ongoing operations and establish a long-term, sustainable capital structure for the Company.

Key Points: 
  • The restructuring is expected to significantly reduce debt and leverage levels and provide substantial additional liquidity to support seamless ongoing operations and establish a long-term, sustainable capital structure for the Company.
  • The Company will continue to pay vendors and suppliers through the expected restructuring process in the ordinary course of business.
  • With the support of our creditors, we have reached an agreement to restructure and strengthen our balance sheet, enhance liquidity and position Diebold Nixdorf for long-term success.
  • The terms of the restructuring support agreement contemplate that the common shares of the restructured Company will be listed on the New York Stock Exchange.